Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066729 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00066729 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 9 participants.
The verdict
NCT00066729, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Interventions
- BIOLOGICAL NY-ESO-1 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2003-06-23 |
| Est. Completion | 2013-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066729
The ClinicalTrials.gov registry entry for NCT00066729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NY-ESO-1 peptide vaccine is the first listed.
NCT00066729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066729 about?
NCT00066729 is a clinical study titled "Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.
What is the current status of trial NCT00066729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2003-06-23. Estimated completion is 2013-08-01.
What interventions are being tested in trial NCT00066729?
The interventions under investigation include: NY-ESO-1 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00066729?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.